Rev Esp Quimioter 2022;35(Suppl.1):46-49

New evidence in severe pneumonia: imipenem/ cilastatin/relebactam

ROSA Mª GIRÓN, AMPARO IBÁÑEZ, ROSA MAR GÓMEZ-PUNTER, TERESA ALARCÓN

Published: 22 April 2022

http://www.doi.org/10.37201/req/s01.11.2022

Imipenem combined with beta-lactamase inhibitor relebactam (IMI/REL) has an extensive bactericidal activity against Gram-negative pathogens producing class A or class C beta-lactamases, not active against class B and class D. The phase 3 clinical trial (RESTORE-IMI-2), double-blind, randomized, evaluated IMI/REL vs. piperacillin-tazobactam (PIP/TAZ) for treatment of hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP), demonstrated non-inferiority at all-cause mortality at 28 days (15.9% vs 21.3%), favorable clinical response at 7-14 days end of treatment (61% vs 59.8%) and with minor serious adverse effects (26.7% vs 32%). IMI/REL is a therapeutic option in HAP and VAP at approved dosage imipenem 500 mg, cilastatin 500 mg and relebactam 250 mg once every 6h, by an IV infusion over 30 min.

Rev Esp Quimioter 2022; 35(Suppl. 1):46-49 [Full-text PDF]